FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.97 USD
0 (0%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
248.12M
54.52M
91.5M
100.39M
37.86M
31.92M
26.91M
22.69M
19.13M
16.12M
Revenue %
-
-78.03
67.81
9.72
-62.28
-15.69
-15.69
-15.69
-15.69
Operating Cash Flow
-67.79M
-207.03M
-237.13M
-166.86M
-85M
-27.28M
-23M
-19.39M
-16.35M
-13.78M
Operating Cash Flow %
-27.32
-379.73
-259.17
-166.21
-224.49
-85.46
-85.46
-85.46
-85.46
Cap Ex
-22.26M
-19.57M
-22.84M
-13.87M
-707k
-5.46M
-4.6M
-3.88M
-3.27M
-2.76M
Cap Ex %
-8.97
-35.9
-24.97
-13.81
-1.87
-17.1
-17.1
-17.1
-17.1
Free Cash Flow
-90.05M
-226.61M
-259.98M
-180.72M
-85.7M
-32.74M
-27.6M
-23.27M
-19.62M
-16.54M
Weighted Average Cost Of Capital
Price
4.97
Beta
Diluted Shares Outstanding
52.22M
Costof Debt
3.91
Tax Rate
After Tax Cost Of Debt
3.91
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
243.72M
Total Equity
259.52M
Total Capital
503.24M
Debt Weighting
48.43
Equity Weighting
51.57
Wacc
6.45
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
248.12M
54.52M
91.5M
100.39M
37.86M
31.92M
26.91M
22.69M
19.13M
16.12M
Operating Cash Flow
-67.79M
-207.03M
-237.13M
-166.86M
-85M
-27.28M
-23M
-19.39M
-16.35M
-13.78M
Cap Ex
-22.26M
-19.57M
-22.84M
-13.87M
-707k
-5.46M
-4.6M
-3.88M
-3.27M
-2.76M
Free Cash Flow
-90.05M
-226.61M
-259.98M
-180.72M
-85.7M
-32.74M
-27.6M
-23.27M
-19.62M
-16.54M
Wacc
6.45
6.45
6.45
6.45
6.45
Pv Lfcf
-30.76M
-24.36M
-19.29M
-15.28M
-12.1M
Sum Pv Lfcf
-101.79M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
6.45
Free Cash Flow T1
-16.87M
Terminal Value
-379.5M
Present Terminal Value
-277.71M
Intrinsic Value
Enterprise Value
-379.5M
Net Debt
172.47M
Equity Value
-551.97M
Diluted Shares Outstanding
52.22M
Equity Value Per Share
-10.57
Projected DCF
-10.57 1.47%
